Evidence map›Paper›PMID 38506533›Full record

ArticlemSystems2024

Outbreak of NDM-5-producing

Junying Zhu, Guangyu Wang, Min Li

Open access · goldAbstract read
In one paragraph

Article in mSystems, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 15 citations in OpenAlex.

  1. Carbapenem-ResistantMicroorganisms · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Characterization of Carbapenem-ResistantInfection and drug resistance · 2026
    Article
  13. Infection and immunity · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Clinical and genomic characterization ofFrontiers in microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Junying Zhu *Department of Laboratory Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-5509-939X
Guangyu Wang *Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Min LiDepartment of Laboratory Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0003-0578-7538
Shanghai Jiao Tong University · CN

Funding

National Key Research and Development Program No. 2022YFC2603800National Natural Science Foundation of China (NSFC) 82172325
6 · The paper itself

Abstract

The high-risk clone

Indexed as

Klebsiella InfectionsKlebsiella pneumoniaeAnti-Bacterial AgentsCarbapenemsChinaDisease OutbreaksDrug Resistance, BacterialEscherichia coliHumansMicrobial Sensitivity TestsMultilocus Sequence TypingPhylogenyAnti-Bacterial AgentsCarbapenemscarbapenem resistanceKlebsiella pneumoniaeoutbreakST307 high-risk clone

Identifiers

PMID38506533
PMCPMC11019902
OpenAlexW4392997219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.